ARTICLE | Emerging Company Profile
A Passage to optimal CNS vectors
Passage uses James Wilson’s AAV vectors, gene therapies targeting the CNS
March 21, 2019 12:44 PM UTC
Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched last month with a $115.5 million series A round led by OrbiMed Advisors.
Passage Bio Inc. co-founder and interim CEO Stephen Squinto told BioCentury that most other companies in the CNS gene therapy space use adeno-associated viral (AAV) serotype 9 (AAV9) vectors because of their tropism for the nervous system. Squinto is also a venture partner at OrbiMed...